Jun 2026 (Q2 FY26) — Aug 5, 2026
Healthpeak Properties Q2 FY26 — Strategic Partnerships and Strong Balance Sheet Drive Growth
Read the full callHealthpeak Properties (DOC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Healthpeak Properties earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 772 | +11.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 52.8 | +66.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
17 of 19 judged targets kept · 16 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Full-year gross proceeds from asset sales, recapitalizations and loan repayments | $1 billion or more | Dec 2025 | the proceeds raised exceed our capital recycling target for the year in a single transaction | Achieved |
| Full-year FFO as adjusted per share | $1.70 to $1.74 | Dec 2025 | We raised our FFO's adjusted guidance range by [ $0.02 ] to $1.73 to $1.77 per share. | Revised Up |
| Lab total occupancy at year-end versus the prior year-end | increase from year-end 2025 to year-end 2026 | Dec 2025 | We ended the quarter with total occupancy increasing by 80 basis points sequentially to 78.5%. That is a 140 basis points increase since year-end 2025. | On Track |
2 of HEALTHPEAK PROPERTIES, INC.'s 35 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 32 more targets are in the full ledger.
Claimed
- Completed strategic partnership with Brookfield, raising $1 billion in cash proceeds and exceeding capital recycling targets.
- Net debt-to-EBITDA improved to 4.7x, reflecting a stronger balance sheet and ample liquidity.
- Outpatient Medical achieved 5% cash re-leasing spreads and increased total occupancy by 20 basis points sequentially to 90.7%.
- Life Science total occupancy increased by 80 basis points sequentially to 78.5%, driven by 381,000 square feet of executed leases.
- Senior Housing same-store portfolio delivered 260 basis points of occupancy growth and 19% NOI growth.
Qualified
- The Boston lab market remains challenged by a significant supply overhang, despite recent increases in market activity.
- Outpatient cash re-leasing spreads decelerated slightly in Q2 compared to Q1, though still strong at 5%.
Price
$18.96 +1.17% · +$0.22
Performance +4.5% 1Y
1Y: $18.14 on 14 Oct 2025 → $18.96. High $22.82 (28 Jul 2026), low $15.78 (23 Dec 2025).
- Previous close
- $18.74
- 52-week range
- $15.78 – $22.82
- One year
- +2.43%
Overview
- Symbol
- DOC
- Sector
- Real Estate
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
17 of 19 judged targets kept · 16 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Full-year gross proceeds from asset sales, recapitalizations and loan repayments | $1 billion or more | Dec 2025 | the proceeds raised exceed our capital recycling target for the year in a single transaction | Achieved |
| Full-year FFO as adjusted per share | $1.70 to $1.74 | Dec 2025 | We raised our FFO's adjusted guidance range by [ $0.02 ] to $1.73 to $1.77 per share. | Revised Up |
| Lab total occupancy at year-end versus the prior year-end | increase from year-end 2025 to year-end 2026 | Dec 2025 | We ended the quarter with total occupancy increasing by 80 basis points sequentially to 78.5%. That is a 140 basis points increase since year-end 2025. | On Track |
Claimed
- Completed strategic partnership with Brookfield, raising $1 billion in cash proceeds and exceeding capital recycling targets.
- Net debt-to-EBITDA improved to 4.7x, reflecting a stronger balance sheet and ample liquidity.
- Outpatient Medical achieved 5% cash re-leasing spreads and increased total occupancy by 20 basis points sequentially to 90.7%.
- Life Science total occupancy increased by 80 basis points sequentially to 78.5%, driven by 381,000 square feet of executed leases.
- Senior Housing same-store portfolio delivered 260 basis points of occupancy growth and 19% NOI growth.
Qualified
- The Boston lab market remains challenged by a significant supply overhang, despite recent increases in market activity.
- Outpatient cash re-leasing spreads decelerated slightly in Q2 compared to Q1, though still strong at 5%.
The full ledger
Open HEALTHPEAK PROPERTIES, INC.’s full ledger
A free account opens 5 company ledgers a month. All 35 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Healthpeak Q1 FY26 — Strong Operational Performance and Strategic Capital Initiatives
Read the full callEvery analysed call
Healthpeak Properties earnings calls (DOC)
Financials
What the filings say
Net profit, year on year: +67% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 700 | 698 | 703 | 694 | 706 | 719 | 753 | 772 |
| Expenses | 665 | 668 | 642 | 652 | 653 | 661 | 747 | 739 |
| Other income | 63 | -33 | -6 | -3 | 13 | 66 | 190 | 27 |
| Interest | 74 | 71 | 73 | 75 | 77 | 81 | 87 | 92 |
| Profit before tax | 99 | -3 | 54 | 40 | 65 | 125 | 196 | 59 |
| Tax rate | 2.0% | 433.3% | 3.8% | 6.0% | −1.9% | 4.8% | 0.1% | −2.4% |
| Net profit | 86 | 5 | 43 | 32 | -117 | 114 | 194 | 53 |
| EPS ($ per share) | 0.12 | — | 0.06 | 0.05 | -0.17 | — | 0.28 | 0.08 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 477 | 505 | 538 | 539 | 547 | 547 | 699 | 695 |
| Total liabilities | 6,206 | 7,365 | 8,573 | 8,111 | 8,483 | 8,774 | 10,881 | 12,034 |
| Total assets | 12,719 | 14,033 | 15,920 | 15,258 | 15,771 | 15,699 | 19,938 | 20,336 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 849 | 846 | 758 | 795 | 900 | 956 | 1,070 | 1,252 |
| Cash from investing | 1,829 | -1,449 | -1,008 | 531 | -876 | -577 | -114 | -1,035 |
| Cash from financing | -2,621 | 647 | 246 | -1,289 | -117 | -337 | -941 | 136 |
| Net cash flow | 58 | 45 | -3 | 38 | -93 | 42 | 15 | 353 |
| Capital expenditure | -582 | -677 | -789 | -760 | -962 | -775 | -737 | -895 |
| Free cash flow | 267 | 169 | -30 | 36 | -62 | 182 | 334 | 357 |
DOC revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Outpatient Medical | — | — | — | — | — | — | 42% | 40% | — |
| Senior Housing | — | — | — | — | — | — | 27% | 28% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
42 filings between Nov 28, 2025 and May 29, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$213.7K
1 sale by 1 insider
Compensation
not trading decisions- 23
- Award — granted as compensation
- 18
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bohn Scott R | — | $213.7K | May 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Thomas John T Director | Award | 1,385 | $21.4K |
| May 29, 2026 | Thomas John T Director | Tax withheld | 78 | $1.5K |
| May 29, 2026 | Brinker Scott M President and CEO | Award | 1,347 | $20.8K |
| May 29, 2026 | Brinker Scott M President and CEO | Tax withheld | 114 | $2.2K |
| May 29, 2026 | Johnston Shawn G EVP and CAO | Award | 1,358 | $21.0K |
| May 29, 2026 | Johnston Shawn G EVP and CAO | Tax withheld | 76 | $1.5K |
| May 29, 2026 | Mabry Adam G CIO | Award | 625 | $9.7K |
| May 29, 2026 | Mabry Adam G CIO | Tax withheld | 43 | $823 |
| May 29, 2026 | Patadia Ankit B. EVP and Treasurer | Award | 1,358 | $21.0K |
| May 29, 2026 | Patadia Ankit B. EVP and Treasurer | Tax withheld | 94 | $1.8K |
| May 29, 2026 | Moses Kelvin O Chief Financial Officer | Award | 937 | $14.5K |
| May 29, 2026 | Moses Kelvin O Chief Financial Officer | Tax withheld | 65 | $1.2K |
| May 12, 2026 | Bohn Scott R CDO and Head of Lab | Sale | 10,989 | $213.7K |
| May 6, 2026 | Griffin R Kent Jr Director | Award | 9,744 | $0 |
| May 6, 2026 | Lewis Sara Grootwassink Director | Award | 9,744 | $0 |
| May 6, 2026 | Connor James B. Director | Award | 9,744 | $0 |
| May 6, 2026 | Weiss Richard A. Director | Award | 9,744 | $0 |
| May 6, 2026 | Cartwright Brian G. Director | Award | 9,744 | $0 |
| May 6, 2026 | Sandstrom Katherine M Director | Award | 9,744 | $0 |
| May 6, 2026 | Lias-Booker Ava Director | Award | 9,744 | $0 |
| Feb 16, 2026 | Alonso Lisa A EVP and Chief HR Officer | Tax withheld | 808 | $13.5K |
| Feb 15, 2026 | Alonso Lisa A EVP and Chief HR Officer | Tax withheld | 495 | $8.3K |
| Feb 7, 2026 | Alonso Lisa A EVP and Chief HR Officer | Tax withheld | 657 | $11.1K |
| Feb 7, 2026 | Thomas John T Director | Tax withheld | 6,454 | $108.7K |
| Feb 6, 2026 | Thomas John T Director | Award | 23,739 | $0 |
| Jan 28, 2026 | Alonso Lisa A EVP and Chief HR Officer | Award | 456 | $0 |
| Jan 28, 2026 | Alonso Lisa A EVP and Chief HR Officer | Award | 3,828 | $0 |
| Jan 28, 2026 | Alonso Lisa A EVP and Chief HR Officer | Tax withheld | 252 | $4.5K |
| Nov 28, 2025 | Thomas John T Director | Tax withheld | 81 | $1.5K |
| Nov 28, 2025 | Thomas John T Director | Award | 1,448 | $21.4K |
| Nov 28, 2025 | Brinker Scott M President and CEO | Award | 1,689 | $25.0K |
| Nov 28, 2025 | Brinker Scott M President and CEO | Tax withheld | 140 | $2.6K |
| Nov 28, 2025 | Johnston Shawn G EVP and CAO | Award | 1,689 | $25.0K |
| Nov 28, 2025 | Johnston Shawn G EVP and CAO | Tax withheld | 92 | $1.7K |
| Nov 28, 2025 | Alonso Lisa A EVP and Chief HR Officer | Award | 338 | $5.0K |
| Nov 28, 2025 | Alonso Lisa A EVP and Chief HR Officer | Tax withheld | 23 | $420 |
| Nov 28, 2025 | Mabry Adam G CIO | Award | 844 | $12.5K |
| Nov 28, 2025 | Mabry Adam G CIO | Tax withheld | 58 | $1.1K |
| Nov 28, 2025 | Patadia Ankit B. EVP and Treasurer | Award | 1,689 | $25.0K |
| Nov 28, 2025 | Patadia Ankit B. EVP and Treasurer | Tax withheld | 115 | $2.1K |
| Nov 28, 2025 | Moses Kelvin O Chief Financial Officer | Award | 810 | $12.0K |
| Nov 28, 2025 | Moses Kelvin O Chief Financial Officer | Tax withheld | 55 | $1.0K |
| Aug 6, 2025 | Thomas John T Director | Purchase | 1,450 | $24.7K |
| Aug 4, 2025 | Brinker Scott M President and CEO | Purchase | 1,490 | $25.1K |
| Jul 31, 2025 | Brinker Scott M President and CEO | Purchase | 2,930 | $50.0K |
| Jul 28, 2025 | Thomas John T Director | Gift | 5,000 | $0 |
| Jul 28, 2025 | Brinker Scott M President and CEO | Purchase | 2,873 | $50.0K |
| May 28, 2025 | Thompson Tommy G Director | Purchase | 5,777 | $99.8K |
| May 9, 2025 | Thompson Tommy G Director | Purchase | 5,700 | $99.0K |
| May 9, 2025 | Brinker Scott M President and CEO | Purchase | 2,750 | $47.8K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HEALTHPEAK PROPERTIES, INC.
Free account. Everything above stays public.
Write why you follow HEALTHPEAK PROPERTIES, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading